ערך בספרים למניה: NAYA Biosciences (NAYA)
Patents for antibodies targeting autoimmune diseases and breast cancer help NAYA Biosciences (NAYA) attract venture capital investments despite R&D expenditures. The book value per share confirms this resilience, with the current value of the metric standing at -19.09. NAYA Biosciences (NAYA) is scaling the expansion of its NY-303 drug for liver cancer therapy by implementing the Flex-NK platform to activate NK cells in tumor treatment.
פילוחי נתונים אנליטיים מרוכזים עבור nayabiosciences.com (NAYA)
Book value per share is defined as the difference between a company's total assets and liabilities, divided by the total number of outstanding securities. This indicator reflects the actual value of net assets, which is critical for NAYA Biosciences (NAYA) as it scales the Flex-NK platform in oncology and reproduction, while the current book value per share illustrates the efficiency of capital management.